Neuroprotective mechanisms and translational potential of therapeutic hypothermia in the treatment of ischemic stroke
Stroke is a leading cause of disability and death, yet effective treatments for acute stroke has been very limited. Thus far, tissue plasminogen activator has been the only FDA-approved drug for thrombolytic treatment of ischemic stroke patients, yet its application is only applicable to less than 4...
Main Authors: | Jin Hwan Lee, James Zhang, Shan Ping Yu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2017-01-01
|
Series: | Neural Regeneration Research |
Subjects: | |
Online Access: | http://www.nrronline.org/article.asp?issn=1673-5374;year=2017;volume=12;issue=3;spage=341;epage=350;aulast=Lee |
Similar Items
-
Experience with therapeutic hypothermia in the treatment of ischemic stroke
by: I E Kalenova, et al.
Published: (2012-06-01) -
Temporal limits of therapeutic hypothermia onset in clinical trials for acute ischemic stroke: How early is early enough?
by: Hangil Lee, et al.
Published: (2020-01-01) -
Stroke and Therapeutic Hypothermia
by: Ozlem Ozkan Kuscu, et al.
Published: (2016-09-01) -
Therapeutic Hypothermia for Acute Air Embolic Stroke
by: Matthew Chang, et al.
Published: (2012-04-01) -
Neuroprotection by Therapeutic Hypothermia
by: Ying-Jian Sun, et al.
Published: (2019-06-01)